ZA200305072B - Manufacturing method of combined vaccine. - Google Patents

Manufacturing method of combined vaccine. Download PDF

Info

Publication number: ZA200305072B
Authority: ZA; South Africa
Prior art keywords: antigen; vaccine; combined; pertussis; hepatitis
Prior art date: 2001-01-10

Application number

ZA200305072A

Other languages

English (en)

Inventor

Kyu-Wan Kim

Hyi-Jeong Ji

Youn-Kyeong Lee

Kim Wan-Kyu Lee Hee-Ku

Won-Kyum Kim

Original Assignee

Lg Life Sciences Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-10

Filing date

2003-06-30

Publication date

2003-09-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19704448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200305072(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-06-30 Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd

2003-09-17 Publication of ZA200305072B publication Critical patent/ZA200305072B/en

Links

229960005486 vaccine Drugs 0.000 title claims description 137
238000004519 manufacturing process Methods 0.000 title claims description 44
102000036639 antigens Human genes 0.000 claims description 151
108091007433 antigens Proteins 0.000 claims description 151
239000000427 antigen Substances 0.000 claims description 145
201000005702 Pertussis Diseases 0.000 claims description 49
238000000034 method Methods 0.000 claims description 44
208000002672 hepatitis B Diseases 0.000 claims description 35
229940024546 aluminum hydroxide gel Drugs 0.000 claims description 33
SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical group O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 claims description 32
239000003463 adsorbent Substances 0.000 claims description 31
229910052782 aluminium Inorganic materials 0.000 claims description 23
238000001179 sorption measurement Methods 0.000 claims description 23
206010013023 diphtheria Diseases 0.000 claims description 21
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
206010043376 Tetanus Diseases 0.000 claims description 17
-1 aluminum ion Chemical class 0.000 claims description 17
101710154643 Filamentous hemagglutinin Proteins 0.000 claims description 15
201000010099 disease Diseases 0.000 claims description 15
101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 claims description 12
101710194807 Protective antigen Proteins 0.000 claims description 8
229960000814 tetanus toxoid Drugs 0.000 claims description 7
230000007935 neutral effect Effects 0.000 claims description 6
239000004094 surface-active agent Substances 0.000 claims description 6
229960003983 diphtheria toxoid Drugs 0.000 claims description 5
238000002156 mixing Methods 0.000 claims description 4
229920000136 polysorbate Polymers 0.000 claims description 2
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims description 2
229950008882 polysorbate Drugs 0.000 claims 1
239000000243 solution Substances 0.000 description 68
239000000523 sample Substances 0.000 description 25
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 19
229940124736 hepatitis-B vaccine Drugs 0.000 description 19
230000036039 immunity Effects 0.000 description 17
229940032024 DPT vaccine Drugs 0.000 description 16
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
238000002255 vaccination Methods 0.000 description 14
210000004027 cell Anatomy 0.000 description 13
239000001963 growth medium Substances 0.000 description 13
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
210000004369 blood Anatomy 0.000 description 12
239000008280 blood Substances 0.000 description 12
239000011780 sodium chloride Substances 0.000 description 12
241000699670 Mus sp. Species 0.000 description 11
239000007853 buffer solution Substances 0.000 description 11
238000012360 testing method Methods 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 10
239000000499 gel Substances 0.000 description 10
241000282693 Cercopithecidae Species 0.000 description 9
230000003247 decreasing effect Effects 0.000 description 9
210000002966 serum Anatomy 0.000 description 9
239000012064 sodium phosphate buffer Substances 0.000 description 9
208000006454 hepatitis Diseases 0.000 description 8
231100000283 hepatitis Toxicity 0.000 description 8
239000000047 product Substances 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
238000005119 centrifugation Methods 0.000 description 7
238000003756 stirring Methods 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical group [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 6
229940024545 aluminum hydroxide Drugs 0.000 description 6
230000007423 decrease Effects 0.000 description 6
230000008569 process Effects 0.000 description 6
238000011160 research Methods 0.000 description 6
239000000377 silicon dioxide Substances 0.000 description 6
239000000126 substance Substances 0.000 description 6
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 6
229940033663 thimerosal Drugs 0.000 description 6
229920001817 Agar Polymers 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108010081690 Pertussis Toxin Proteins 0.000 description 5
239000008272 agar Substances 0.000 description 5
238000007796 conventional method Methods 0.000 description 5
238000003018 immunoassay Methods 0.000 description 5
230000003993 interaction Effects 0.000 description 5
239000000203 mixture Substances 0.000 description 5
229940031346 monovalent vaccine Drugs 0.000 description 5
239000008055 phosphate buffer solution Substances 0.000 description 5
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
229920000053 polysorbate 80 Polymers 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
239000003053 toxin Substances 0.000 description 5
231100000765 toxin Toxicity 0.000 description 5
241000894006 Bacteria Species 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
239000004472 Lysine Substances 0.000 description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 4
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
229910052921 ammonium sulfate Inorganic materials 0.000 description 4
235000011130 ammonium sulphate Nutrition 0.000 description 4
230000002708 enhancing effect Effects 0.000 description 4
239000012488 sample solution Substances 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
239000011734 sodium Substances 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
241000588832 Bordetella pertussis Species 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
229920001213 Polysorbate 20 Polymers 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
230000008901 benefit Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
230000008859 change Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000009472 formulation Methods 0.000 description 3
150000004676 glycans Chemical class 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
239000012535 impurity Substances 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
238000001802 infusion Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
150000003904 phospholipids Chemical class 0.000 description 3
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
229920001282 polysaccharide Polymers 0.000 description 3
239000005017 polysaccharide Substances 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
230000000392 somatic effect Effects 0.000 description 3
241000193403 Clostridium Species 0.000 description 2
241000186216 Corynebacterium Species 0.000 description 2
108010053187 Diphtheria Toxin Proteins 0.000 description 2
102000016607 Diphtheria Toxin Human genes 0.000 description 2
101710154606 Hemagglutinin Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
101710176177 Protein A56 Proteins 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
108010055044 Tetanus Toxin Proteins 0.000 description 2
239000013504 Triton X-100 Substances 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
239000004411 aluminium Substances 0.000 description 2
239000000356 contaminant Substances 0.000 description 2
238000012258 culturing Methods 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000000185 hemagglutinin Substances 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
239000002245 particle Substances 0.000 description 2
229940068977 polysorbate 20 Drugs 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 description 2
229940118376 tetanus toxin Drugs 0.000 description 2
229940124856 vaccine component Drugs 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
210000005253 yeast cell Anatomy 0.000 description 2
229910002019 Aerosil® 380 Inorganic materials 0.000 description 1
101710186708 Agglutinin Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
229920002271 DEAE-Sepharose Polymers 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
208000005331 Hepatitis D Diseases 0.000 description 1
101710146024 Horcolin Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
206010022678 Intestinal infections Diseases 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
101710189395 Lectin Proteins 0.000 description 1
101710179758 Mannose-specific lectin Proteins 0.000 description 1
101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
201000005505 Measles Diseases 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
208000005647 Mumps Diseases 0.000 description 1
101100026709 Mus musculus Nprl3 gene Proteins 0.000 description 1
241000286209 Phasianidae Species 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
241000288906 Primates Species 0.000 description 1
241001510071 Pyrrhocoridae Species 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
208000037386 Typhoid Diseases 0.000 description 1
241000812633 Varicus Species 0.000 description 1
241000700605 Viruses Species 0.000 description 1
RXHSGRQJJBSBPN-UHFFFAOYSA-L [Na+].[Na+].Cl.OP([O-])([O-])=O Chemical compound [Na+].[Na+].Cl.OP([O-])([O-])=O RXHSGRQJJBSBPN-UHFFFAOYSA-L 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000910 agglutinin Substances 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
239000008364 bulk solution Substances 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000003795 desorption Methods 0.000 description 1
238000001784 detoxification Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
208000001848 dysentery Diseases 0.000 description 1
125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
229960004443 hemophilus influenzae b vaccines Drugs 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
201000011475 meningoencephalitis Diseases 0.000 description 1
229940101532 meted Drugs 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
208000010805 mumps infectious disease Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
229940124733 pneumococcal vaccine Drugs 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
238000012552 review Methods 0.000 description 1
201000005404 rubella Diseases 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
101150115956 slc25a26 gene Proteins 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000012475 sodium chloride buffer Substances 0.000 description 1
WTWSHHITWMVLBX-DKWTVANSSA-M sodium;(2s)-2-aminobutanedioate;hydron Chemical compound [Na+].[O-]C(=O)[C@@H](N)CC(O)=O WTWSHHITWMVLBX-DKWTVANSSA-M 0.000 description 1
239000002689 soil Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000012353 t test Methods 0.000 description 1
201000008297 typhoid fever Diseases 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Mycology (AREA)
Immunology (AREA)
Virology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

ZA200305072A 2001-01-10 2003-06-30 Manufacturing method of combined vaccine. ZA200305072B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
KR10-2001-0001290A KR100401423B1 (ko)	2001-01-10	2001-01-10	혼합 백신의 제조 방법

Publications (1)

Publication Number	Publication Date
ZA200305072B true ZA200305072B (en)	2003-09-17

Family

ID=19704448

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200305072A ZA200305072B (en)	2001-01-10	2003-06-30	Manufacturing method of combined vaccine.

Country Status (21)

Country	Link
US (2)	US20040048336A1 (de)
EP (1)	EP1349572B1 (de)
JP (1)	JP3977257B2 (de)
KR (1)	KR100401423B1 (de)
CN (1)	CN1228086C (de)
AR (1)	AR032391A1 (de)
AT (1)	ATE373485T1 (de)
AU (1)	AU2002219693B2 (de)
BR (1)	BR0206391A (de)
CA (1)	CA2434421C (de)
DE (1)	DE60222529T2 (de)
ES (1)	ES2291466T3 (de)
IL (1)	IL156791A0 (de)
MX (1)	MXPA03006154A (de)
MY (1)	MY143688A (de)
PE (1)	PE20020758A1 (de)
PL (1)	PL211005B1 (de)
RU (1)	RU2264226C2 (de)
UY (1)	UY27118A1 (de)
WO (1)	WO2002055105A1 (de)
ZA (1)	ZA200305072B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0642355B1 (de)	1992-05-23	1998-07-15	SMITHKLINE BEECHAM BIOLOGICALS s.a.	Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
GB0505996D0 (en)	2005-03-23	2005-04-27	Glaxosmithkline Biolog Sa	Fermentation process
GB0522765D0 (en) *	2005-11-08	2005-12-14	Chiron Srl	Combination vaccine manufacture
CA2654014A1 (en)	2006-05-31	2007-12-06	Silvio Buzzi	Pharmaceutical use of protein molecules immunologically correlated to diphtheria toxin
GB0616306D0 (en) *	2006-08-16	2006-09-27	Novartis Ag	Vaccines
ATE511398T1 (de) *	2006-09-07	2011-06-15	Glaxosmithkline Biolog Sa	Inaktiviertes poliovirus mischimpfstoff
GB0822633D0 (en) *	2008-12-11	2009-01-21	Novartis Ag	Formulation
IT1398927B1 (it)	2009-06-25	2013-03-28	Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi	Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
GB0917647D0 (en)	2009-10-08	2009-11-25	Glaxosmithkline Biolog Sa	Expression system
CN102363041A (zh) *	2011-11-17	2012-02-29	成都欧林生物科技股份有限公司	不含防腐剂疫苗的制作工艺
KR101518473B1 (ko)	2013-03-14	2015-05-07	(주)바이오인디스트	애완견의 바이러스성 전염병 예방 및 치료용 복합 난황 항체 조성물 및 그 제조방법
AR102548A1 (es)	2014-11-07	2017-03-08	Takeda Vaccines Inc	Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
MA40920A (fr)	2014-11-07	2017-09-12	Takeda Vaccines Inc	Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci
KR20220076405A (ko) *	2020-11-30	2022-06-08	주식회사 엘지화학	알루미늄 부형제를 이용하여 다가 혼합백신 내 백일해 균 유래 엔도톡신 제거 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU188847B (en) *	1983-02-22	1986-05-28	Human Oltoanyagtermeloe Es Kutato Intezet,Hu	Process for producing liophylized combined vaccines
CA1213234A (en) *	1983-03-30	1986-10-28	Akihiro Ginnaga	Method for the production of ha fraction containing protective antigens of bordetella pertussis and pertussis vaccine
US4649192A (en) *	1985-05-30	1987-03-10	Smith Kline-Rit	Method for the isolation and purification of hepatitis B surface antigen using polysorbate
EP0251575B2 (de) *	1986-06-17	2002-11-13	Chiron Corporation	Hepatitis-Delta-Diagnostika und Impfstoffe, ihre Herstellung und Verwendung
JPH085804B2 (ja) *	1988-04-28	1996-01-24	財団法人化学及血清療法研究所	Ａ型及びｂ型肝炎混合アジュバントワクチン
EP0484621A3 (en) *	1990-07-11	1992-08-26	American Cyanamid Company	Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
EP0642355B1 (de) *	1992-05-23	1998-07-15	SMITHKLINE BEECHAM BIOLOGICALS s.a.	Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
EP0845270B1 (de) *	1996-03-23	2004-10-27	The Research Foundation For Microbial Diseases Of Osaka University	Funktionelles antigenfragment von tetanustoxin und tetanusvakzine
GB9611501D0 (en) *	1996-06-03	1996-08-07	Smithkline Beecham Biolog	Vaccine compositions
AU714493B2 (en) *	1996-07-02	2000-01-06	Connaught Laboratories Limited	Multivalent DTP-polio vaccines
GB9623233D0 (en) *	1996-11-07	1997-01-08	Smithkline Beecham Biolog	Vaccine composition
CA2303105A1 (en) *	1997-09-15	1999-03-25	Pasteur Merieux Msd	Multivalent vaccines
GB9806456D0 (en) *	1998-03-25	1998-05-27	Smithkline Beecham Biolog	Vaccine composition

2001
- 2001-01-10 KR KR10-2001-0001290A patent/KR100401423B1/ko active IP Right Grant
2002
- 2002-01-08 MY MYPI20020056A patent/MY143688A/en unknown
- 2002-01-09 ES ES02729589T patent/ES2291466T3/es not_active Expired - Lifetime
- 2002-01-09 UY UY27118A patent/UY27118A1/es not_active IP Right Cessation
- 2002-01-09 DE DE60222529T patent/DE60222529T2/de not_active Revoked
- 2002-01-09 PL PL369433A patent/PL211005B1/pl not_active IP Right Cessation
- 2002-01-09 AR ARP020100060A patent/AR032391A1/es unknown
- 2002-01-09 PE PE2002000008A patent/PE20020758A1/es active IP Right Grant
- 2002-01-09 AT AT02729589T patent/ATE373485T1/de not_active IP Right Cessation
- 2002-01-09 JP JP2002555838A patent/JP3977257B2/ja not_active Expired - Fee Related
- 2002-01-09 CN CNB028035933A patent/CN1228086C/zh not_active Expired - Fee Related
- 2002-01-09 RU RU2003124660/15A patent/RU2264226C2/ru active
- 2002-01-09 EP EP02729589A patent/EP1349572B1/de not_active Revoked
- 2002-01-09 AU AU2002219693A patent/AU2002219693B2/en not_active Ceased
- 2002-01-09 BR BR0206391-3A patent/BR0206391A/pt active Search and Examination
- 2002-01-09 MX MXPA03006154A patent/MXPA03006154A/es active IP Right Grant
- 2002-01-09 CA CA2434421A patent/CA2434421C/en not_active Expired - Fee Related
- 2002-01-09 WO PCT/KR2002/000034 patent/WO2002055105A1/en active IP Right Grant
- 2002-01-09 US US10/465,930 patent/US20040048336A1/en not_active Abandoned
2003
- 2003-01-09 IL IL15679103A patent/IL156791A0/xx not_active IP Right Cessation
- 2003-06-30 ZA ZA200305072A patent/ZA200305072B/en unknown
2009
- 2009-03-19 US US12/407,445 patent/US20090181050A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2002219693B2 (en)	2006-03-16
RU2003124660A (ru)	2005-01-10
CN1228086C (zh)	2005-11-23
UY27118A1 (es)	2002-08-30
RU2264226C2 (ru)	2005-11-20
EP1349572B1 (de)	2007-09-19
CN1484531A (zh)	2004-03-24
MXPA03006154A (es)	2003-09-16
PL211005B1 (pl)	2012-03-30
CA2434421C (en)	2012-02-21
ATE373485T1 (de)	2007-10-15
EP1349572A1 (de)	2003-10-08
JP2004517866A (ja)	2004-06-17
BR0206391A (pt)	2004-07-27
PL369433A1 (en)	2005-04-18
KR100401423B1 (ko)	2003-10-17
EP1349572A4 (de)	2004-09-15
WO2002055105A1 (en)	2002-07-18
KR20020060298A (ko)	2002-07-18
US20090181050A1 (en)	2009-07-16
PE20020758A1 (es)	2002-08-29
JP3977257B2 (ja)	2007-09-19
MY143688A (en)	2011-06-30
DE60222529D1 (de)	2007-10-31
CA2434421A1 (en)	2002-07-18
ES2291466T3 (es)	2008-03-01
AR032391A1 (es)	2003-11-05
US20040048336A1 (en)	2004-03-11
IL156791A0 (en)	2004-02-08
DE60222529T2 (de)	2008-06-19

Publication	Publication Date	Title
US20090181050A1 (en)	2009-07-16	Manufacturing Method of Combined Vaccine
RU2194531C2 (ru)	2002-12-20	Поливалентные ассоциированные коклюшно-дифтерийно-столбнячно (акдс)-полиомиелитные вакцины
CA1253073A (en)	1989-04-25	Antigenic preparations and isolation of such preparations
JP4980868B2 (ja)	2012-07-18	非細胞性百日咳ワクチンおよびその製造方法
JP2012255015A (ja)	2012-12-27	ワクチンに使用するためのｈｂｖ抗原の精製
NZ224422A (en)	1990-11-27	Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
AU2002219693A1 (en)	2003-02-06	Manufacturing method of combined vaccine
RU2447898C2 (ru)	2012-04-20	Вакцина ipv-dpt
US20140112954A1 (en)	2014-04-24	Method for preparing hbv vaccine comprising aluminum adjuvant
JP2002226397A (ja)	2002-08-14	非細胞性ワクチン
US20120269847A1 (en)	2012-10-25	Antigen purification process for pertactin antigen
US5237052A (en)	1993-08-17	Antigenic preparations and isolation of such preparations
EP2592137A1 (de)	2013-05-15	Fermentierungsmedium ohne Bestandteile tierischen Ursprungs zur Herstellung von Diphtherie-Impfstoffen zur menschlichen Impfung
WO2020043874A1 (en)	2020-03-05	Conjugated haemophilus influenzae vaccine using bordetella outer membrane vesicle
CN112912097A (zh)	2021-06-04	免疫原性蛋白和组合物